Insights into the Purification of C1-esterase Inhibitor from Human Plasma

Author:

Verma Sachin1,Dolia Sheetal1,Makadia Savan1,Kumar Narendra2

Affiliation:

1. Intas Pharmaceuticals Ltd (Plasma Fractionation Unit), Ahmedabad, Gujarat, India

2. Department of Biotechnology and Bioengineering, Institute of Advanced Research, Gandhinagar, Koba Institutional Area, Gujarat, India

Abstract

Hereditary angioedema (HAE) is a rare but often life-threatening genetic disorder caused by either lack of or dysfunctional C1-esterase inhibitor (C1-I3NH). C1-INH is a high-cost therapy for HAE. Because plasma-derived C1-INH has a higher half-life than other therapeutics, it may be considered a suitable treatment option for HAE. However, the high cost of plasma-derived C1-INH may make the therapy unaffordable to some patients. Herein, we review the C1-INH purification processes used to date to identify the reasons for the high costs of this therapy and assess the scope of improvements in the purification processes to develop a cost-effective product. A literature search was conducted in PubMed and Google Scholar in January 2023 to identify the relevant articles. The following keywords were used: “C1 esterase inhibitor,” “hereditary angioedema,” and “C1 esterase inhibitor purification from human plasma.” All English-language articles published from 1960 to February 2021 were included. Several plasma products can be purified using the Cohn fractionation process; this decreases the cost of individual products. However, many C1-INH purification strategies developed to date fail to purify other products from the unused plasma fraction (ie, the fraction remaining after C1-INH purification) because of changes in the physical characteristics of the plasma, such as pH and ionic strength; as a result, it is unavailable for the Cohn fractionation process, leading to the high cost of C1-INH. Using cutting-edge purification technologies and more efficient virus removal steps can decrease manufacturing costs, thereby increasing the affordability and safety of the product.

Publisher

SAGE Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3